In diffuse large B-cell lymphoma (DLBCL), combining p53 reactivation (via stapled peptide ATSP-7041) with BCL-2 inhibition (ABT-263) using CD19-targeted polymersomes has shown reduced toxicity and improved efficacy in preclinical models [118]. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.